Intrarosa vs Brisdelle: Which One Keeps Working Longer for Menopause Symptoms?

What These Two Drugs Actually Do (and Why Comparing Them Is Unusual)

Intrarosa and Brisdelle are both FDA-approved for menopause-related symptoms, but they address almost entirely different problems. Knowing which problem you are trying to solve is the first step before any durability comparison matters.

Intrarosa contains prasterone 6.5 mg, a synthetic form of DHEA inserted vaginally each night. Once inside vaginal epithelium, intracrine enzymes convert it locally into estrogens and androgens that restore tissue without meaningful systemic hormone exposure. Brisdelle contains paroxetine mesylate 7.5 mg, the only FDA-approved non-hormonal prescription option specifically indicated for vasomotor symptoms (VMS). It is the lowest available dose of paroxetine and its mechanism is serotonin reuptake inhibition in the thermoregulatory centers of the hypothalamus.

The symptom overlap between the two drugs is small. Intrarosa does not reliably reduce hot flashes. Brisdelle does not restore vaginal moisture or reduce painful intercourse. A woman with severe night sweats and vaginal dryness may end up on both.

Why "Durability" Means Different Things for Each Drug

For Intrarosa, durability means sustained tissue restoration: the vaginal pH, superficial cells, and moisture stay improved as long as you continue the nightly insert. The drug does not build tolerance over time.

For Brisdelle, durability means sustained symptom reduction in hot flash frequency and severity. SSRIs can lose some effect over months in mood disorders, and the same question applies to VMS. The 24-week trial data are reassuring but do not answer the multi-year question with certainty.

Intrarosa (Prasterone): Evidence for Long-Term GSM Relief

Intrarosa has the strongest long-term RCT dataset of any non-systemic vaginal treatment for genitourinary syndrome of menopause (GSM). GSM affects roughly 50 to 60 percent of postmenopausal women and is progressive if untreated.

The 52-Week Key Trial

The registration trials submitted to the FDA included a 52-week double-blind RCT in postmenopausal women with moderate-to-severe dyspareunia. Women using prasterone 6.5 mg nightly showed statistically significant improvements versus placebo across all four co-primary endpoints: percentage of superficial cells, percentage of parabasal cells, vaginal pH, and the woman's own rating of dyspareunia severity. At 12 weeks, mean dyspareunia severity dropped by 1.42 points on a 0-to-3 scale compared with 1.05 for placebo (p = 0.0001). Those gains held through week 52, with no attenuation of effect seen over time. That durability signal across a full year sets Intrarosa apart from many topical alternatives.

What Happens If You Stop

Unlike systemic hormone therapy, the structural changes from vaginal DHEA do not persist after you stop. GSM is a chronic condition tied to ongoing estrogen and androgen deficiency. Most clinicians advise continuing Intrarosa indefinitely, or switching to another maintenance therapy, because the underlying deficiency does not resolve.

Systemic Absorption: Reassuring but Not Zero

Serum DHEA, testosterone, and estradiol levels in the 52-week trial stayed within the normal postmenopausal range throughout the year. That finding underlies the argument for using Intrarosa in women who have relative contraindications to systemic estrogen, though the data in women with active breast cancer or a history of hormone-receptor-positive breast cancer remain limited. The Menopause Society position is that vaginal hormonal products are generally low-risk but that shared decision-making with an oncologist is appropriate in breast cancer survivors.

Intrarosa and PCOS or Androgen-Sensitive Conditions

Because prasterone converts to androgens as well as estrogens in vaginal tissue, women with a history of androgen-sensitive conditions (hyperandrogenism, androgen-sensitive cancers) should discuss the theoretical risk with their clinician. No RCT has enrolled women with active PCOS in the postmenopausal Intrarosa trials, representing a genuine evidence gap. What we know is based on systemic absorption data showing DHEA and testosterone levels staying within postmenopausal norms, not on direct PCOS outcome data.

Brisdelle (Paroxetine 7.5 mg): Evidence for Long-Term VMS Relief

Brisdelle targets vasomotor symptoms specifically. Hot flashes affect up to 80 percent of women during the menopause transition and can persist for 7 or more years after the final menstrual period in a meaningful subset.

The Key 24-Week Trials

Two randomized, double-blind, placebo-controlled trials formed the FDA submission for Brisdelle. In the primary efficacy trial, 1,175 postmenopausal women with at least 7 moderate-to-severe hot flashes per day were randomized to paroxetine 7.5 mg or placebo. At week 4, women on paroxetine experienced a mean reduction of 4.3 hot flashes per day versus 3.4 for placebo (p < 0.001). At week 24, the reduction was 5.9 versus 4.6 (p < 0.001). The effect was consistent across the full 24-week period, with no sign of tolerance developing within that window.

Beyond 24 Weeks: What the Evidence Does and Does Not Say

No long-term RCT of Brisdelle runs past 24 weeks. That is a real limitation. Data from general paroxetine use in depression show sustained serotonin reuptake inhibition over years, but VMS physiology is not identical to depressive physiology. Real-world observational data suggest that women who respond at 4 to 8 weeks tend to continue responding, though abrupt discontinuation can trigger VMS rebound and discontinuation syndrome even at 7.5 mg. Be candid with your clinician about how long you have been on it before stopping.

Brisdelle in Perimenopause

A clinically meaningful subset of women in the Brisdelle trials were perimenopausal (still having irregular periods). Paroxetine 7.5 mg reduced VMS in this group comparably to postmenopausal women in the trials, which matters because perimenopausal women often face barriers to systemic hormone therapy when they still have a uterus and irregular bleeding. The Menopause Society 2023 position statement recognizes low-dose paroxetine as an effective non-hormonal option for women who cannot or choose not to use hormone therapy.

SSRI Class Effects and Women-Specific Concerns

Paroxetine carries class-level concerns that disproportionately affect women:

• Sexual dysfunction. SSRIs reduce libido and delay orgasm in a meaningful proportion of women. At 7.5 mg, rates in the Brisdelle trials were lower than at standard antidepressant doses, but real-world experience varies.
• Weight change. Paroxetine is among the SSRIs most associated with weight gain. Perimenopausal and postmenopausal women already face metabolic shifts, so baseline weight and metabolic status should be documented before starting.
• Tamoxifen interaction. This is non-negotiable. Paroxetine is a strong CYP2D6 inhibitor and substantially reduces tamoxifen conversion to active endoxifen. Women taking tamoxifen for breast cancer should not use paroxetine, including Brisdelle. This makes Brisdelle inappropriate for the large subset of women with hormone-receptor-positive breast cancer on adjuvant tamoxifen.

Pregnancy, Lactation, and Contraception

This section is required for both drugs and the information differs significantly between them.

Intrarosa in Pregnancy and Lactation

Intrarosa is contraindicated in pregnancy. DHEA is a sex-steroid precursor, and exogenous administration during pregnancy carries theoretical risk of androgen excess to a female fetus. No adequate human pregnancy data exist. Reproductive-age women using prasterone vaginally for an off-label indication (such as premature ovarian insufficiency) must use reliable contraception. The FDA prescribing information states that Intrarosa is not for use in premenopausal women in the approved indication, but off-label use in younger women does occur in fertility contexts under specialist supervision.

Lactation transfer of vaginally applied prasterone has not been studied. Given the local-to-systemic absorption profile, risk is considered low but unquantified. Breastfeeding women should avoid it until data exist.

Brisdelle in Pregnancy and Lactation

Brisdelle is contraindicated in pregnancy. Paroxetine is classified by FDA as a drug with human data showing fetal risk (formerly Pregnancy Category D). First-trimester paroxetine exposure has been associated with a small but statistically significant increase in cardiac septal defects in observational data. Neonatal adaptation syndrome (jitteriness, feeding difficulties, respiratory distress) occurs in newborns exposed late in pregnancy. Women of reproductive age who are not postmenopausal and who use Brisdelle for perimenopausal VMS should use reliable contraception and discuss risk with their prescriber.

Paroxetine passes into breast milk. The relative infant dose is low but not negligible. Brisdelle is not recommended during lactation. Venlafaxine or gabapentin carry different lactation profiles if a non-hormonal VMS option is needed while breastfeeding; that is a conversation with your clinician.

Who Each Drug Is Right For (and Not Right For), by Life Stage

Postmenopause: GSM Is Your Main Problem

Intrarosa is the stronger fit. The 52-week durability data are specific to postmenopausal women. If you have vaginal dryness, painful sex, or recurrent UTIs tied to atrophic tissue, Intrarosa addresses the root physiology. Brisdelle will do nothing for these symptoms.

Postmenopause: Hot Flashes Are Your Main Problem

Brisdelle is the appropriate first-line consideration among non-hormonal options, alongside venlafaxine and gabapentin, and now fezolinetant (a NK3 receptor antagonist with longer-term data). If you are not a candidate for systemic hormone therapy and tamoxifen is not in your regimen, Brisdelle is a reasonable choice.

Perimenopause: Irregular Cycles, Mounting Hot Flashes

Brisdelle has the better fit here because Intrarosa's indication is specifically postmenopausal GSM. Perimenopausal women still producing meaningful estrogen typically do not have severe GSM yet. Hot flashes and night sweats tend to arrive first.

Women with Breast Cancer History

The picture is complicated. Intrarosa's local conversion to estrogens makes oncologists cautious in hormone-receptor-positive breast cancer survivors, though the low systemic absorption is the key counter-argument in shared decision-making. Brisdelle is explicitly unsuitable for women on tamoxifen due to CYP2D6 inhibition. Neither drug has been adequately studied in breast cancer survivors in long-term RCTs, which is an honest and important evidence gap.

Women with PCOS Entering Perimenopause

PCOS confers higher baseline androgen levels and insulin resistance. There are no PCOS-specific trials for either drug. Intrarosa's androgen-generating mechanism raises a theoretical question in women with androgen-sensitive features, though postmenopausal PCOS phenotype is attenuated. Brisdelle's weight-gain risk is a legitimate concern given metabolic comorbidities common in PCOS. Both choices require individualized conversation.

Switching from Intrarosa to Brisdelle (or Vice Versa)

The question "should I switch from Intrarosa to Brisdelle?" comes up most often when:

1. A woman starts with vaginal symptoms (Intrarosa), then develops significant hot flashes.
2. A woman starts with hot flashes (Brisdelle), then develops GSM as menopause progresses.
3. A clinician mistakenly views these as interchangeable options for "menopause."

In scenarios 1 and 2, the practical answer is usually that you add the second drug rather than switching, because the symptom targets do not overlap. Stopping Intrarosa to start Brisdelle makes sense only if cost or pill burden is the driver and you have decided that hot flashes are a greater priority than vaginal symptoms.

If you are stopping Brisdelle after more than a few weeks of use, taper rather than stop abruptly. Even at 7.5 mg, paroxetine discontinuation syndrome can cause dizziness, electric-shock sensations, and rebound VMS. Your clinician can walk you through a dose-reduction plan.

Stopping Intrarosa requires no taper. GSM symptoms typically return within 4 to 8 weeks of stopping as the vaginal epithelium reverts to its atrophic state.

Head-to-Head: Durability Summary Table

| Feature | Intrarosa (Prasterone 6.5 mg vaginal) | Brisdelle (Paroxetine 7.5 mg oral) | |---|---|---| | Primary target symptom | Vaginal dryness, dyspareunia (GSM) | Hot flashes, night sweats (VMS) | | Longest RCT duration | 52 weeks | 24 weeks | | Tolerability over time | No tolerance seen at 52 weeks | No tolerance seen at 24 weeks | | Effect after stopping | Reverses within weeks | Taper needed; rebound VMS risk | | Systemic hormone exposure | Low; stays in postmenopausal range | None (non-hormonal) | | Key drug interaction | None established | Strong CYP2D6 inhibitor (tamoxifen) | | Pregnancy | Contraindicated | Contraindicated (human fetal risk data) | | Breast cancer caution | Use with oncologist guidance | Avoid with tamoxifen | | Life stage with most evidence | Postmenopause | Perimenopause and postmenopause |

What the Evidence Gap Means for You

Women's health trials have historically enrolled predominantly postmenopausal women aged 50 to 65 in good general health, excluding those with breast cancer, PCOS, premature ovarian insufficiency, or significant comorbidities. The 52-week Intrarosa trial and the 24-week Brisdelle trials follow that pattern. What happens in women over 70 using Intrarosa for a decade, or in a perimenopausal woman with PCOS on Brisdelle for three years, is genuinely unknown. That is not a reason to avoid either drug. It is a reason to have an annual check-in with your prescriber rather than assuming indefinite use is automatically safe or effective.

As Dr. Elena Vasquez, WomanRx clinical reviewer and board-certified OB-GYN, notes: "The most common mistake I see is clinicians and patients treating Intrarosa and Brisdelle as alternatives to each other. They answer different questions. The better comparison for Intrarosa is ospemifene or vaginal estrogen. The better comparison for Brisdelle is venlafaxine or fezolinetant. Asking which of these two is more durable is a bit like asking whether ibuprofen or antihistamine works longer for your cold, you have to specify which symptom you are treating."

The Menopause Society 2023 position statement on nonhormonal management of menopause acknowledges that most non-hormonal therapies have trial data limited to 12 to 24 weeks, while VMS and GSM often persist for years. That gap in long-term evidence affects the entire non-hormonal field, not just Brisdelle.

Practical Steps Before Your Next Appointment

Identify your primary symptom clearly before the visit. If it is vaginal dryness or pain with sex, ask specifically about Intrarosa or vaginal estrogen, and ask how long your clinician expects you to continue. If it is hot flashes disrupting sleep or daily function, ask about Brisdelle, venlafaxine, or fezolinetant, and ask what the plan looks like at six months and at one year.

Bring your current medication list. The tamoxifen-paroxetine interaction is clinically significant and reduces active tamoxifen metabolite endoxifen by up to 64 percent, which may compromise breast cancer treatment outcomes. That single interaction rules out Brisdelle for a large subset of women.

Ask about contraception if you are perimenopausal and not yet confirmed postmenopausal (defined as 12 consecutive months without a period). Both drugs are contraindicated in pregnancy, and perimenopausal women can still ovulate unpredictably.